Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis

Vaccine

Volumn 24, Issue 18, 2006, Pages 3909-3920

  Oliveira Freitas, E ^a   Casas, C P ^a   Borja Cabrera, G P ^a   Santos, F N ^a   Nico, D ^a   Souza, L O P ^a   Tinoco, L W ^a   da Silva, B P ^a   Palatnik, M ^a   Parente, J P ^a   Palatnik de Sousa, C B ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Deacylated saponins; FML vaccine; Murine visceral leishmaniasis; QS21 saponin; Quillaja saponaria Molina; Saponins

Indexed keywords

ALDEHYDE; CELLULOSE; GAMMA INTERFERON; GLUCOSE; IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; PARASITE ANTIGEN; QS 21; QUERCETIN; RUTOSIDE; SAPONIN; SAPONIN DERIVATIVE; SAPONIN PURE; SUCROSE; TERPENE;

ACYLATION; AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEACYLATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LYMPHOCYTE ACTIVATION; MOUSE; MOUSE STRAIN; NONHUMAN; NORMAL HUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUILLAJA; SPLEEN; VACCINATION; VISCERAL LEISHMANIASIS; WEIGHT GAIN;

ACYLATION; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CHROMATOGRAPHY, ION EXCHANGE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYSIS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; LECTINS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PLANT EXTRACTS; PROTOZOAN VACCINES; QUILLAJA; SAPONINS; SPLEEN;

EID: 33646135059     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.034     Document Type: Article

References (33)

1. Santos W.R., de Lima V.M.F., Paraguai de Souza E., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 (2002) 30-43
2. Santos W.R., Aguiar I.A., Paraguai de Souza E., de Lima V.F.M., Palatnik M., and Palatnik-de-Sousa C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21 32 (2003) 4668-4676
3. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M., et al. A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 19 (2001) 1082-1092
4. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante). Vaccine 20 (2002) 3277-3284
5. ® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 (2005) 4805-4810
6. Saraiva E.M., Mendes-Aguiar C.O., Paraguai de Souza E., Borja-Cabrera G.P., Fampa P., Parra L.E., et al. The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24 (2006) 2423-2431
7. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies?. Am J Trop Med Hyg 52 (1995) 287-292
8. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza W., Okada L.Y.H., Trivellato F.A.A., Kawasaki J.K.A., et al. Effective Immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 (2004) 2234-2243
9. ® in dogs of Brazilian endemic areas. Proceedings of the Third World Congress on Leishmaniosis (Worldleish III). Palermo, Italy (2005) 116
10. Palatnik-de-Sousa C.B., Santos W.R., Casas C.P., Paraguai de Souza E., Tinoco L.W., da Silva B.P., et al. Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins. Vaccine 22 19 (2004) 2470-2479
11. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8 (2003) 934-943
12. Kensil C.R., Patel U., Lennick M., and Marciani D.J. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146 (1991) 431-437
13. 13C NMR spectroscopy. Carbohydr Res 280 (1996) 1-14
14. Higuchi R., Tokimitsu Y., Fujioka T., Komori T., Kawasaki T., and Oakenful D.G. Structure of deacylsaponins obtained from the bark of Quillaja saponaria. Phytochemistry 26 (1987) 229-235
15. Higuchi R., and Komori T. Structures of compounds derived from the acyl moieties of quillajasaponin. Phytochemistry 26 (1987) 2357-2360
16. Higuchi R., Tokimitsu Y., and Komori T. An acylated triterpenoid saponin from Quillaja saponaria. Phytochemistry 27 (1988) 1165-1168
17. Guo S., Falk E., Kenne L., Ronnberg B., and Sundquist B.G. Triterpenoid saponins containing an acetylated branched d-fucosyl residue from Quillaja saponaria Molina. Phyotchemistry 53 (2000) 861-868
18. Bradley D.J., and Kirkley K. Regulation of Leishmania population within the host. The variable course of Leishmania donovani infections in the mice. Clin Exp Immunol 30 (1977) 119-129
19. Palatnik C.B., Borojevic R., Previato J.O., and Mendonça-Previato L. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect Immun 57 (1989) 754-763
20. Palatnik de Sousa C.B., Paraguai de Souza E., Gomes E.M., and Borojevic R. Experimental murine Leishmania donovani infection: immunoprotection by the fucose mannose ligand (FML). Braz J Med Biol Res 27 (1994) 547-551
21. Palatnik de Sousa C.B., Moreno M.B., Paraguai de Souza E., and Borojevic R. The FML vaccine (fucose-mannose ligand) protects hamsters from experimental Kala-Azar. Ciência e Cultura (J Braz Assoc Adv Sci) 46 (1994) 290-296
22. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
23. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Castro Z.R., Nussenzweig R.S., Schmeckpeper B., et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccines of defined HLA genotypes. J Infect Dis 182 (2000) 1486-1496
24. Evans T.G., McElrath M.J., Matthews T., Montefiori D., Weinhold K., Wolff M., et al. NIAID AIDS Vaccine Evaluation Group. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19 (2001) 2080-2091
25. Liu G., Anderson C., Scaltreto H., Barbon J., and Kensil C.R. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine 20 (2002) 2808-2815
26. Soltysik S., Wu J.Y., Recchia J., Wheeler D.A., Newman M.J., Coughlin R.T., et al. Structure/function studies of QS21 adjuvant: assessment of triterpen-aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13 (1995) 1403-1410
27. Rhodes J. Covalent chemical events in immune induction: fundamental and therapeutics aspects. Immunol Today 17 (1996) 436-441
28. Marciani D.J., Pathak A.K., Reynolds R.C., Seitz L., and May R.D. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int Immunopharmacol 1 (2001) 813-818
29. Cleland J.L., Kensil C.R., Lim A., Jacobsen N.E., Basa L., Spellman M., et al. Isomerization and formulation stability of the vaccine adjuvant QS-21. J Pharm Sci 85 (1996) 22-28
30. Van Setten D.C., ten Hove G.J., Wiertz E.J.H.J., Kamerling J.P., and Van de Werken G. Multiple-stage tandem mass spectrometry for structural characterization of saponins. Anal Chem (1998) 4401-4419
31. Pillion D.J., Amsden J.A., Kensil C.R., and Recchia J. Structure-function relationship among Quillaja saponins serving as excipient for nasal and ocular delivery of insulin. J Pharm Sci 85 (1996) 518-524
32. Marciani D. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int Immunopharmacol 1 (2001) 813-818
33. Arakawa T., Dix D.B., and Chang B.S. The effects of protein stabilizers on aggregation induced by multiple stress. Yahukagu Zasshi 123 (2003) 957-961